CD19 and non-Hodgkin lymphoma: The greatest success of this therapeutic approach is seen in CD19+ haematologic malignancies such as acute lymphocytic leukaemia and non-Hodgkin’s lymphoma, with remission rates above 90% and worldwide regulatory agency approval of several CD19-targeting CAR T products.4,5